Ovarian Neoplasm Epithelial Clinical Trial
Official title:
The Effects of Two Hemodilution Methods on Vascular Endothelial Function in Patients Undergoing Primary Debulking Gynaecological Surgery
Primary cytoreductive surgery for ovarian cancer is an ideal setting to evaluate endothelial function under ANH and AHH, as the procedure is associated with moderately high blood loss. As the technique has not yet been described in this setting, investigators designed a pilot study to evaluate ANH and AHH in patients planned to undergo primary cytoreduction during perioperative period, with the intent of proceeding to a randomized trial if results were favorable.
Using a computer-generated random number table, patients were randomized to three groups: Control Group(n=30), ANH Group(n=30) and AHH Group(n=30). Patients underwent standard preoperative preparation for cytoreductive surgery according to institutional standards.All patients who underwent a standard anesthesia protocol and similar surgical procedures were considered for the analysis. For this purpose, investigators only included patients who underwent the following interventions: radical hysterectomy, bilateral adnexectomy, one or more bowel resection, peritonectomy, pelvic lymphadenectomy and extended periaortic lymphadenectomy. The patient would be ruled out of the experiment when the participant was accompanied with any kind of serious complications such as wakening delay and drug allergy. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06466382 -
OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy
|
N/A | |
Recruiting |
NCT05001282 -
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRĪ±)
|
Phase 1/Phase 2 | |
Recruiting |
NCT05960630 -
MIRRORS-RCT Pilot: Role of Robotic Interval Cytoreductive Surgery for Advanced Ovarian Cancer
|
N/A | |
Recruiting |
NCT04111978 -
MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
|
Phase 3 | |
Recruiting |
NCT03509246 -
Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients
|
Phase 2 | |
Recruiting |
NCT04402333 -
Minimally Invasive Robotic Surgery, Role in Optimal Debulking Ovarian Cancer, Recovery & Survival
|
||
Recruiting |
NCT04780945 -
Functional Analysis of BRCAness
|
Phase 2 | |
Recruiting |
NCT03015376 -
Inherited Susceptible Genes Among Epithelial Ovarian Cancer
|
||
Recruiting |
NCT03883542 -
Sub-type Specific Genomic Mutations in sBOTs
|
||
Recruiting |
NCT05605535 -
Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer
|
Phase 2 |